Fasting plasma glucose [fasting is defined as no calorific intake for at least 8 hours]:\r\n* >= 126 mg/dL for those patients without a pre-existing diagnosis of type 2 diabetes mellitus\r\n* >= 167mg/dL for those patients with a pre-existing diagnosis of type 2 diabetes mellitus
Patients may not have a diagnosis of diabetes mellitus as defined by: 1) known diagnosis of diabetes mellitus (DM), or 2) active treatment for DM, or 3) fasting glucose level ? 126 mg/dl, or 4) hemoglobin A1c ? 6.0% obtained within 30 days prior to registration
Uncontrolled diabetes: a glycated hemoglobin (Hg A1C) > 7% within 14 days prior to registration; the same criterion will be used in patients with confirmed diagnosis of diabetes mellitus who have been on a stable dietary or therapeutic regimen for this condition in the last three months
Diagnosis of diabetes mellitus; participants with a history of transient glucose intolerance due to corticosteroid administration may be enrolled if all other inclusion/exclusion criteria are met.
Diagnosis of diabetes mellitus
Patients with a history of or with a current diagnosis of diabetes mellitus
Diagnosis of diabetes mellitus or current therapy with any drugs used to treat diabetes mellitus, including but not limited to insulin, sulfonylureas, metformin, rosiglitazone (Avandia), and pioglitazone (Actos) within 14 days of study day 1
Diagnosis of diabetes mellitus uncontrolled with oral hypoglycemic agents or insulin.
Diagnosis of diabetes mellitus type 2
Diagnosis of diabetes
Patients will also need to satisfy one of the following diabetic criteria: (1) documented diagnosis of piabetes mellitus (diabetes) or pre-diabetes, (2) use of diabetic medication, (3) presence of diabetes risk factors which will prompt diabetic screening of the treating physician’s choice leading to a diagnosis of pre-diabetes or diabetes or the finding of a glycosylated hemoglobin (HbA1c) >= 5.7%
Previous diagnosis of diabetes mellitus
Have diagnosis of diabetes
Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible
Patients must have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic or locally advanced disease not amenable to surgical resection; (NOTE: a designation of type I or type II should be made by the local pathologist if possible); mixed histologies containing type I or type II will be allowed provided that they contain >= 50% of the papillary component
Patients must have tissue available and be willing to submit for independent pathologic review in order to classify type I versus type II papillary disease
Type 1 or 2 diabetes requiring anti-hyperglycemic medication (e.g. metformin, glipizide, insulin)
Patients with Diabetes Type I or uncontrolled Type II as judged by the Investigator
Diabetes mellitus type 1
Patients with controlled Type 1 diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.
Type I or type II diabetes, or Hgb A1c > 6.5%
Type 1 or Type 2 diabetes mellitus requiring insulin at study entry
EXCLUSION - INFUSION: Uncontrolled autoimmune disease needing systemic steroids or steroid sparing agents except for hypothyroidism or type I diabetes
Participant has a concurrent diagnosis of type I or type II diabetes that is being treated with insulin or an oral antidiabetic agent; (participants whose type II diabetes is controlled with diet and/or exercise alone are eligible provided they meet all other eligibility criteria)
Part B: Must have a type of malignancy that is being studied.
Patients may have neurofibromatosis type 1 or 2
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible
Participants with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone or participants with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study with approval by the medical monitor
Uncontrolled diabetes mellitus. Patients with Type II diabetes are eligible if they require only oral hypoglycemic agents and fasting blood glucose level is ?120. Patients with Type I diabetes are eligible if their glycosylated hemoglobin (HbAlc) is ?7.
Uncontrolled (per investigator judgment) type I or type II diabetes mellitus.
Patients with uncontrolled type 1 diabetes mellitus. If on a stable insulin regimen may be eligible, after discussion with principal investigator.
History of multiple sclerosis, type 1 diabetes mellitus (DM) or Guillain-Barre syndrome
Patients with certain diseases such as active autoimmune disease, type I diabetes, hypothyroidism that needs hormone replacement, active infection, psychiatric disorder.
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen are eligible
Has a confirmed diagnosis of type 1 diabetes or type 2 diabetes that has been diagnosed by an HbA1c ? 6.5, or is on any hypoglycemic medications (insulin, metformin, etc)
FOR ALL PHASES (Ib AND II): Type I diabetes or patients on insulin therapy are not allowed; uncontrolled type II diabetes not allowed (glycosylated hemoglobin [HbA1c] > 7.5)
History of autoimmune disease except for controlled, treated thyroidism or Type 1 diabetes
Patients with certain diseases such as active autoimmune disease, type I diabetes, hypothyroidism that needs hormone replacement, active infection, psychiatric disorder
Tumor type:
Subjects with uncontrolled type I or II diabetes mellitus
Patients with auto-immune disease, with the exception of type I diabetes or treated hypothyroidism.
Type 1 diabetes mellitus or type 2 diabetes mellitus actively receiving treatment
Insulin-dependent diabetes; patients with type II diabetes must meet the inclusion criteria outlined above
History of autoimmune disease except treated/stable hypothyroidism, Type 1 diabetes mellitus, and protocol-specified dermatologic conditions
Patient with an established diagnosis of diabetes mellitus type I or uncontrolled type II
Patients with active autoimmune disease, with exceptions of vitiligo, type I diabetes mellitus, hypothyroidism and psoriasis.
Patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible
Patients with uncontrolled type 1 or type 2 diabetes; patients with an elevated risk of hyperglycemia should be excluded from study
Diabetic patients (type I or II diabetes mellitus) must have baseline hemoglobin (Hb)A1c levels NOT higher than 8.5% at study entry
For the Diabetes Expansion Cohort - Subjects with known history of type 2 diabetes\n             mellitus that are well-controlled on a stable dose of oral anti-diabetic agents such\n             as metformin and/or sulfonylureas for 4 weeks prior to screening.
For the Diabetes Expansion Cohort - Subjects who have type 1 diabetes mellitus,\n             maturity onset diabetes of the young, hyperglycemia due to reasons other than type 2\n             diabetes mellitus.
Patients must not have type I or II diabetes that requires anti-hyperglycemic medication
History of autoimmune disease except controlled/treated hypothyroidism, type 1 diabetes mellitus, or certain skin disorders
Type 1 diabetes or uncontrolled Type 2 diabetes
Patients with an established diagnosis of diabetes mellitus type I or not controlled type II
Subjects with uncontrolled type I or type II diabetes mellitus (defined as HgbA1c > 8).
Patients with uncontrolled Diabetes Type I or Type II
Type 1 or Type 2 diabetes mellitus requiring anti-hyperglycemic medications
Histologically or cytologically confirmed recurrent or metastatic SCCHN\r\n* All primary sites are eligible excluding World Health Organization (WHO) type III or Epstein–Barr virus (EBV) nasopharyngeal (WHO type I and WHO type II allowed as long as they are EBV negative)
history of Diabetes Mellitus, type 1 or type 2,
Epithelial type
Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.
Patients with type II diabetes currently already on metformin
Type I or II diabetes mellitus with HbA1c > 8.5% at Screening.
Known history of autoimmune disease (with the exceptions of medically-controlled hypothyroidism and type I diabetes mellitus)
Patients with type II diabetes mellitus that is well controlled by dietary measures alone and have a hemoglobin A1c (HgA1c) < 8% are eligible to participate; patients found to have a fasting glucose >= 7 mmol/L (>= 126 mg/dL) or glycosylated hemoglobin > 8% (64 mmol/mol) at screening should be assessed for appropriate management according to local policy; those in whom dietary measures alone provide good diabetic control will be eligible for inclusion; type I or II diabetes mellitus requiring either insulin or oral hypoglycemics for routine management will be excluded
Patients with diabetes type I or uncontrolled type II (HbA1c > 8 % assessed locally) as judged by the investigator
History of type I diabetes mellitus; if a patient has type II diabetes, they must have a hemoglobin (hemoglobin A1C) =< 8%; patients with a screening fasting glucose > 120 mg/dL will be excluded
Subjects with Type II diabetes are only allowed if their HbA1C is less than 8 percent at study entry.
Previously diagnosed diabetes mellitus Type I. Subjects with Type II diabetes are allowed if entry criteria are fulfilled
History of Type 1 or Type 2 diabetes requiring regular medication
Patients must not have active or history of clinically significant autoimmune disorders/conditions including type I diabetes; type II diabetes, vitiligo, stable hypothyroidism, and thyroid disease well controlled with thyroid replacement will not be considered exclusion criteria
Patients must not have active or history of clinically significant autoimmune disease, defined as requiring systemic therapy, such as type I diabetes; type II diabetes, vitiligo, stable hypothyroidism, and thyroid disease well controlled with thyroid replacement will not be considered exclusion criteria
Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible.
Type I or II diabetes mellitus with HbA1c > 8.5% at screening (modified by amendment 1)
Patient with type 1 diabetes mellitus or not adequately controlled type 2 diabetes mellitus
Type 1 diabetes or uncontrolled Type 2 diabetes
History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes
Type 1 or 2 diabetes requiring antihyperglycemic medication
Patients with Diabetes Type I or uncontrolled Type II (HbA1c > 59 mmol/mol assessed locally) as judged by the Investigator
Subject has Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus and currently being treated with insulin or sulfonylureas.
Fracture is closed, Gustilo Type I or II.
DONOR: History of type I or type II diabetes mellitus
Subjects with type 1 or type 2 diabetes mellitus
Diabetes mellitus, unless it is type II diabetes adequately controlled with anti-diabetic agents (A1c < 7)
Type 1 or Type 2 diabetes
Type I Diabetes
Type 1 or 2 diabetes mellitus
History of Type I or Type II diabetes mellitus requiring insulin
Type I diabetes
Type II diabetes requiring chronic therapy with insulin
History of Type 1 or 2 diabetes mellitus requiring regular medication (other than metformin or other oral hypoglycemic agents) or fasting glucose ?160 mg/dL at the prestudy visit. If a diabetic cohort is enrolled, only subjects with a medical history of controlled Type 1 or 2 diabetes mellitus will be enrolled in the cohort.
Type 1 or 2 diabetes requiring anti-hyperglycemic medication
Patients with a known history of type 1 or type 2 diabetes mellitus
Type I diabetes or uncontrolled type II diabetes
Type 1 or type 2 diabetes
Type 1 diabetes
type 1 diabetes
Reported current diagnosis or history of type I diabetes or type 2 diabetes.
Any type of ostomy
Type I diabetes mellitus
Any disease type
Group III: Participants with well-controlled vascular risk factors, such as treated hypertension, treated hyperlipidemia or well-controlled type II diabetes (glucose levels < 250) may be included
Diabetes type I or II, or currently on medications to reduce blood sugar
Participants with type 2 diabetes, documented stomach ulcers and pulmonary embolism
Patients with diabetes type 1 or uncontrolled type II (HbA1c > 8% assessed locally)
History of autoimmune disease. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study.
Other illness that in the opinion of the investigator would exclude the patient from participating in this study, including uncontrolled diabetes mellitus, cardiac disease
Uncontrolled diabetes as assessed by the investigator
Uncontrolled diabetes mellitus
Uncontrolled diabetes mellitus
Uncontrolled diabetes mellitus
Uncontrolled diabetes
Patients with serious, uncontrolled, concomitant disorder(s) such as diabetes mellitus
No uncontrolled hypertension (>= 180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen.
Uncontrolled diabetes or symptomatic hyperglycemia
Uncontrolled diabetes mellitus, cardiovascular disease, active serious infection or other condition which, in the opinion of treating physician, would make this protocol unreasonably hazardous for the patient
Uncontrolled hypertension or diabetes mellitus
Uncontrolled diabetes mellitus defined as a Hemoglobin A1C? 7% in patients with a prior history of diabetes, prior to study enrollment.
Uncontrolled diseases other than cancer will be excluded. Subjects with chronic diseases that are well controlled (e.g., diabetes mellitus, hypertension) are eligible.
Uncontrolled diabetes mellitus
Uncontrolled diabetes
Uncontrolled diabetes mellitus
Not deemed a candidate for concurrent CRT for medical reasons, such as uncontrolled infection (including human immunodeficiency virus [HIV]), or uncontrolled diabetes mellitus which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
Uncontrolled diabetes mellitus
Subject has uncontrolled diabetes mellitus
Uncontrolled diabetes
Uncontrolled endocrine disorders including diabetes mellitus, hypothyroidism, or hyperthyroidism.
Uncontrolled diabetes
Uncontrolled diabetes mellitus
Uncontrolled hypertension or uncontrolled diabetes mellitus
Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial
History of uncontrolled diabetes mellitus or diabetic neuropathy
Uncontrolled hypertension, or uncontrolled diabetes mellitus
Uncontrolled diabetes mellitus.
Diabetes mellitus uncontrolled by medication
Uncontrolled diabetes mellitus
Any other severe, uncontrolled medical condition, including uncontrolled diabetes mellitus or unstable congestive heart failure.
Uncontrolled diabetes mellitus.
Not deemed a candidate for concurrent chemoradiation for medical reasons, such as uncontrolled infection (including human immunodeficiency virus [HIV]), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
Uncontrolled diabetes
Uncontrolled diabetes on appropriate therapy
Uncontrolled diabetes mellitus or inadequately controlled hypertension
Uncontrolled diabetes mellitus
Patients with serious medical complications, such as serious heart disease, cerebrovascular accidents, uncontrolled diabetes mellitus, uncontrolled hypertension, pulmonary fibrosis, interstitial pneumonitis, active bleeding, an active gastrointestinal ulcer, or a serious neurological disorder
Diabetes mellitus uncontrolled
Uncontrolled heart failure or hypertension or uncontrolled diabetes mellitus
Uncontrolled heart failure or hypertension or uncontrolled diabetes mellitus
Diabetes mellitus uncontrolled
Uncontrolled diabetes mellitus
Medical conditions such as uncontrolled hypertension, uncontrolled diabetes mellitus, cardiac disease that would, in the opinion of the investigator, make this protocol unreasonably hazardous
Uncontrolled diabetes
Uncontrolled diabetes (HA1C > 10%) despite optional therapy
Uncontrolled diabetes
Patients with uncontrolled diabetes mellitus
The patient has uncontrolled diabetes mellitus (despite therapeutic intervention) and occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to the first dose of study drug.
Patients with uncontrolled diabetes mellitus
Uncontrolled diabetes mellitus, hypothyroidism, or hyperthyroidism
Have uncontrolled diabetes mellitus or uncontrolled hyperglycemia
Currently has uncontrolled diabetes (at time of screening or enrollment)
Uncontrolled diabetes mellitus (fasting blood sugar > 200 mg/dl) at screening
Uncontrolled diabetes mellitus as defined by a random blood sugar of > 200 mg/dl not being monitored by their primary care physician
Uncontrolled hypertension or other uncontrolled chronic disease (e.g. diabetes mellitus, thyroid disease, pulmonary disease, etc.)
Uncontrolled diabetes, untreated hypothyroidism
Uncontrolled diabetes mellitus
Uncontrolled diabetes mellitus as defined by a random blood sugar of > 200 mg/dl not being monitored by their primary care physician
Medical condition such as uncontrolled infection (including human immunodeficiency virus [HIV]), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases)
Uncontrolled medical condition (e.g., uncontrolled insulin dependent diabetes mellitus).
Uncontrolled diabetes mellitus, cardiovascular disease, active serious infection or other condition which, in the opinion of treating physician, would make this protocol unreasonably hazardous for the patient
Uncontrolled diabetes; subjects with diabetes mellitus are not excluded if the condition is well-controlled (glycated hemoglobin [A1C] < 7.5)
Subject has uncontrolled diabetes mellitus, in the judgment of the Principal Investigator.
Uncontrolled diabetes mellitus
Patients with uncontrolled diabetes
Uncontrolled diabetes mellitus
Patients with controlled diabetes are allowed on study; controlled diabetes is defined as fasting blood sugar (FBS) = 130 mg/dL or less, and patients whose FBS can be brought in this range with medical therapy are eligible for trial inclusion
Patients who have insulin dependent diabetes are not eligible
Patients with a history of diabetes
Active diabetes insipidus
Severe diabetes that is not currently controlled,
Patients with diabetes controlled by diet or medication are allowed on trial; controlled diabetes is defined as FBG < 130 mg/kL in the context of this study
History of diabetes and on active diabetes treatment with pharmacotherapy (oral hypoglycemics or insulin)
Have poorly controlled diabetes defined as HbA1c values of> 7.5%. Participants with preexisting, well-controlled diabetes are not excluded.
Subjects with diabetes.
Currently on medication for diabetes or hypercholesterolemia
Poorly controlled diabetes, fasting blood sugar (FBS) >= 200 mg/dL
Part E: Have insulin-dependent (type I) diabetes or a history of gestational diabetes
Patients with diabetes on metformin; patients with diabetes and not on metformin will be eligible if it is deemed safe after consultation with the patient physician managing diabetes
Subjects that have been previously diagnosed with type 2 diabetes or steroid-induced diabetes must also meet the additional following criteria:\r\n* Diagnosed with diabetes >= 6 months prior to enrollment\r\n* Hemoglobin A1C (HbA1C) =< 8% at screening visit
No history of diabetes
Patients with diabetes who have evidence of complications from their diabetes, such as end organ sequelae of diabetes or Hemoglobin A1c > 7%.
Diabetic patients with poorly controlled diabetes.
Patients with diabetes are eligible for this trial; all diabetic patients who are enrolled on this study should discuss the need to change their diabetes management regimen with their primary care physician or endocrinologist prior to enrollment
Participants with poorly controlled diabetes or with evidence of clinically significant diabetic vascular complications
Poorly controlled diabetes
Diabetes is not exclusionary provided the patient is not maintained with either oral medications or insulin
Have poorly controlled diabetes
Diabetes that is poorly controlled
Poorly controlled diabetes
Patients with clinically manifested diabetes
Patients with uncontrolled diabetes or insulin resistance
Poorly controlled Type 1 or 2 diabetes
Patients with diabetes requiring insulin or requiring more than one non-insulin hypoglycemia agents
Patients with controlled diabetes are allowed on study; controlled diabetes is defined as fetal bovine serum (FBS) =< 130 mg/dL in the context of this study
Uncontrolled diabetes mellitus. i. The glycemic targets for subjects with diabetes should take into consideration age, comorbidities, life expectancy, and functional status of the subjects and follow established guidelines (eg, International Diabetes Federation, the European Diabetes Working Party guidelines, and the American Diabetes Association). For younger (< 70 years old) or subjects with life expectancy ? 10 years, the target glycosylated hemoglobin, type A1C (HbA1c) should be < 7.0%. The target HbA1c for older (? 70 years old) subjects or subjects with life expectancy < 10 years should be < 8.0%. Consultation with an endocrinologist is recommended when deciding if diabetes is optimally controlled. c. Chronic symptomatic congestive heart failure (Class III or IV of the New York Heart Association Classification for Heart Disease). d. Active central nervous system involvement as documented by spinal fluid cytology or imaging. e. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia. f. Other concurrent severe and/or uncontrolled concomitant medical conditions that could cause unacceptable safety risks or compromise compliance with protocol.
Diabetes must be controlled prior to enrollment
Patients with uncontrolled diabetes (as determined by the investigator); well-controlled diabetic patients with fasting glucose < 150 are eligible if they have been on stable doses of medications for diabetes for at least 4 weeks prior to study entry
Patients with poorly controlled diabetes
Diabetes is not exclusionary provided the patient is not maintained with either oral medications or insulin
Uncontrolled or poorly controlled diabetes
Uncontrolled diabetes at the time of cytoreduction; all patients with diabetes must be optimized on their diabetes regimen prior to initiating pasireotide\r\n* If a patient is diabetic: uncontrolled diabetes as defined by hemoglobin A1c (HbA1c) > 8%* despite adequate therapy
Patients with poorly or uncontrolled diabetes in the opinion of the physician(s)
History of diabetes with retinopathy requiring treatment
Diabetes (defined by being on oral hypoglycemics or insulin)
Using medication to treat diabetes
Patients with a history of diabetes
Suspected or diagnosed diabetes (with the exception of gestational diabetes);
Uncontrolled diabetes (controlled diabetes per the American Diabetes Association and International Diabetes Center’s Glycemic Target Goals is hemoglobin A1C < 7%)
History of diabetes
Diabetes
Diabetes
Is being treated for diagnosed diabetes or autoimmune disease
Medication-treated diabetes
Have diabetes
Diabetes requiring drug therapy
Poorly or uncontrolled diabetes in the opinion of the physician(s)
Patients with diabetes who are taking insulin or oral agents
Diagnosed with diabetes
Subjects with a history of diabetes;
Patients with controlled diabetes are allowed on study; controlled diabetes is defined as < 130 ml/dL for the sake of this study
On treatment with any drug for diabetes
Currently being treated for diabetes or meeting criteria for new diagnosis of diabetes
Diabetes being treated with other than diet and lifestyle
No history of diabetes
Patients with insulin-dependent diabetes
Poorly controlled diabetes
Major or chronic medical disease, including heart disease, poorly controlled diabetes, etc., to be adjudicated by the principal investigator
Major or chronic medical disease, including heart disease, poorly controlled diabetes, etc., to be adjudicated by the principal investigator
